Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Oct;85(4):1044-1046.
doi: 10.1016/j.jaad.2021.01.098. Epub 2021 Feb 3.

Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial

Jerry Tsai  1 , Anna L Chien  1 , Noori Kim  1 , Saleh Rachidi  1 , Brian M Connolly  1 , Hester Lim  1 , Sabrina Sisto Alessi César  1 , Sewon Kang  1 , Luis A Garza  2
Affiliations
Randomized Controlled Trial

Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial

Jerry Tsai et al. J Am Acad Dermatol. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None disclosed.

Figures

Figure 1.
Figure 1.. Change in facial erythema (a*) before and after treatment with topical timolol 0.5% gel-forming solution across all participants.
Colorimeter and computer aided image analysis (CAIA)-measured erythema (a*) at each visit for sides of the face assigned to early treatment (baseline – week 16) and delayed treatment (week 8 – week 16). Colorimeter a* measured with Chroma Meter CR-400 at a standardized point of the malar cheek (intersection of the midpupillary line and line drawn laterally from the ipsilateral nasal ala). Computer-aided image analysis (CAIA) a* obtained by converting cross-polarized photographs to 8-bit grayscale a* images with ImageJ software, manually outlining the cheek (infraorbital, zygomatic, and mandibular regions), and measuring average pixel intensity across the region. Both measures of erythema indicate red-green chromaticity with different scales; colorimeter a* may range from-60 (green) to +60 (red), while CAIA a* may range from 0 (green) to 255 (red). Shaded regions on graphs indicate times when participants received treatment. Horizontal band and diamond represent the median and mean respectively; bottom and top of each box, first and third quartiles; lower error bar extends to the lowest data point within 1.5 times the interquartile range from the first quartile; upper error bar extends to the highest data point within 1.5 times the interquartile range from the third quartile. Data points beyond 1.5 times the interquartile range above the third quartile or below the first quartile are plotted individually as outliers. P-values calculated from mixed-effects models using t-tests with Satterthwaite’s method and corrected for multiple comparisons with Benjamini-Hochberg procedure. *adjusted P<.05 compared to baseline, *** adjusted P<.001 compared to baseline. BL, baseline; W4, week 4; W8, week 8; W12, week 12; W16, week 16; W20, week 20.
See this image and copyright information in PMC

References

    1. Fowler J, Jarratt M, Moore A, et al.Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology. 2012;166(3):633–641. - PMC - PubMed
    1. Boger WP 3rd. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28Suppl:235–242. - PubMed
    1. Gandolfi SA. Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma. Investigative Ophthalmology & Visual Science. 1990;31(2):354–358. - PubMed
    1. Ilkovitch D, Pomerantz RG. Brimonidin eeffective but may lead to significant rebound erythema. J Am Acad Dermatol. 2014;70(5):e109–110. - PubMed
    1. Okwundu N, Cline A, Feldman SR. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. J Dermatolog Treat. 2019:1–7. - PubMed